Canakinumab Reduces Risk for Gout Flares, But Not Serum Uric Acid Levels
An exploratory analysis of a canakinumab clinical trial has shown the interleukin 1β inhibitor may significantly reduce patients’ risk for gout flares. During the study, patients using canakinumab experienced this decreased risk, but the treatment did not change serum uric acid levels...
Source: The Rheumatologist - Category: Rheumatology Authors: Lara C. Pullen, PhD Tags: Conditions Crystal Arthritis anti-interleukin canakinumab flare Gout Source Type: research